B-cell Chronic Lymphoid Malignancies Markers

NCT ID: NCT04952974

Last Updated: 2021-07-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

420 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-14

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lymphoid chronic B-cell malignancies are frequent pathologies that affect adults, with a very variable prognosis and treatment (some of them can remain untreated). The diagnosis of these malignancies relies on the study of the morphology of tumoral cells and the expression by these cells of several markers, mainly via a technical approach called flow cytometry. Because the markers currently used remain imperfect, additional ones are needed for an accurate diagnosis that affect both prognosis and treatment.

In addition, because numerous markers are used at the diagnosis, there is a need of tools that synthetize the multi-dimensional structure of the data obtained.

The primary purpose of this study is to detect new markers that can be of help for the diagnosis of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies.

The secondary purpose of this study is to obtain a statistical algorithm that allow a good prediction of the different sub-types of chronic B-cell malignancies mainly using the results of flow cytometry.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia Marginal Zone Lymphoma Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Mantle Cell Lymphoma Hairy Cell Leukemia Follicular Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients over 18 years-old with of Marginal Zone Lymphoma and other B-cell chronic lymphoid malignancies
* patients that gave their informed consent for the conservation of blood or bone marrow cells (primary objective 1)
* patients that gave their informed consent for the retrospective use of their clinical and biological data

Exclusion Criteria

* patients under guardianship or curatorship
* patients who did not gave their consent for the use of their cells and/or data
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laurent MAUVIEUX, MD, PhD

Role: STUDY_DIRECTOR

Hematology Laboratory - Strasbourg University Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hematology Laboratory - Strasbourg University Hospitals

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laurent MAUVIEUX, MD, PhD

Role: CONTACT

33 3 88 12 75 27

Saïd CHAYER, PhD, HDR

Role: CONTACT

33 3 88 11 66 90

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laurent MAUVIEUX, MD, PhD

Role: primary

33 3 88 12 75 27

Saïd CHAYER, PhD, HDR

Role: backup

33 3 88 11 66 90

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8205

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.